Europe minimally invasive surgical instruments market is projected to grow at a CAGR of 8.32% during the forecast period to reach US$9.559 billion by 2027, from US$5.464 billion in 2020.
Because of the limited popularity of robots, most minimally invasive surgery is currently performed by surgeons using surgical instruments. The equipment is mostly hand-held minimally invasive surgical instruments with a modest operational flexibility end effector that opens and closes. They are better than standard devices because they allow smaller incisions and faster recovery. Furthermore, compared to traditional procedures, minimally invasive surgical instruments provide benefits such as lower costs, less pain, and reduced trauma than open surgeries, which are likely to impact market growth positively during the projection period. Moreover, the increasing number of operations is likely to boost the market growth during the forecast period in the region.
An increase in the elderly population coupled with an upsurge in the prevalence of chronic diseases is expected to drive the growth of the European minimally invasive surgical instruments market.
According to the data by Eurostat, in 2020, more than a fifth of the EU population, or 20.6 percent, was estimated to be 65 or older. Moreover, between 2020 and 2100, the proportion of people aged 80 and up in the EU population is expected to increase by two and a half times, from 5.9% to 14.6 percent. According to NCD Alliance, chronic diseases have become more common in Europe in recent decades, owing to an aging population, frequently afflicting persons of working age. Over a third of Europeans aged 15 and up have a chronic ailment, and two out of every three people over the age of 65 will have at least two chronic disorders. For instance, according to the State of Health in the EU, Germany Health Profile 2019, the proportion of persons aged 65 and up in Germany is increasing as a result of rising life expectancy and diminishing fertility rates. In 2017, one in every five Germans was above the age of 65, and this number is expected to climb to one in every three by 2050. A total of 58 percent of Germans aged 65 and up said they had at least one chronic disease, which is slightly higher than the rest of the EU. According to WHO, chronic diseases are estimated to account for 92 percent of all deaths in Spain, with cardiovascular diseases (31 percent) and malignancies (28 percent) accounting for the majority of these. According to a report published in 2019 by the Bertelsmann Foundation, over 70,000 thyroid surgeries are performed in Germany each year. Furthermore, as per the European Society of Cardiology's 2019 report, more than 11 million people in Europe suffer from cardiovascular disorders each year. The cost to Europe's economies is high, totaling EUR 210 billion every year. According to research published by the Società Italiana di Medicina Generale in 2019, the number of Italians affected by gastroesophageal reflux disease climbed from 6.2 percent in 2007 to 17.9 percent in 2017. As a result, the rising number of gastrointestinal illnesses is likely to fuel market expansion by increasing the adoption of minimally invasive instruments.
Major developments by the key players in the market are expected to drive the growth of the European minimally invasive surgical instruments market throughout the forecast period.
In November 2019, avateramedical GmbH, a visionary German medical technology firm, announced that the CE conformity evaluation procedure for its avatera system for robot-assisted, minimally invasive surgery was completed successfully. All four parts of the system can now bear the CE mark: the tools, surgical robot and control unit, the endoscopes, and the sterile components. As a result, avatera is officially approved in the European Economic Area for minimally invasive laparoscopy, which is currently utilized mostly in gynecology and urology. Moreover, in July 2021, Alesi Surgical Limited, a leading developer of minimally invasive surgery technology, successfully raised £9.4 million in capital from new and existing investors. The funds generated will be used to help the company meet its commercial and R&D targets. It will enable the completion and commercialization of a research and development project that integrates ultra-vision technology into energy-based equipment used in laparoscopic and open surgical procedures. Similarly, Surge-on Medical, a Netherlands start-up in the domain of minimally invasive surgery, launched an equity crowd fundraising campaign in August 2019. The campaign collaborated between EIT Health and aescuvest.eu, a German crowdfunding portal. Such developments in the market of minimally invasive surgical instruments are anticipated to propel market expansion in the region further.
COVID-19 had an adverse influence on the European minimally invasive surgical instruments market as the number of surgeries in the region decreased substantially in 2020. This can be attributed to the rules and containment regulations imposed by the governments in the region to limit the spread of the virus. For instance, as per the data by National Health Service (NHS), in England and Wales, the total number of surgical procedures performed in 2020 was 3,102,674, compared to the expected figure of 4,671,338. This reflects a 33.6 percent decrease in surgical activity across the country.
|Market size value in 2020||US$5.464 billion|
|Market size value in 2027||US$9.559 billion|
|Growth Rate||CAGR of 8.32% from 2020 to 2027|
|Forecast Unit (Value)||USD Billion|
|Segments covered||Type, Application, End-User, And Country|
|Regions covered||Germany, France, Italy, Spain, United Kingdom, Netherlands, Ireland, Austria, Belgium, Others|
|Companies covered||Medtronic, Stryker Corporation, Zimmer Biomet, Microline Surgical, Siemens Healthineers, Olympus Corporation, Intuitive Surgical Inc., Surge-on Medical, Smith & Nephew, B. Braun Melsungen AG|
|Customization scope||Free report customization with purchase|
Key Market Segments
Intuitive Surgical Inc.
Smith & Nephew
B. Braun Melsungen AG
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.